Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
[en] The acyclic nucleoside phosphonate (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) was used topically for the treatment of persistent mucocutaneous infections in two cases. One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet. A bone marrow transplant recipient developed orofacial lesions due to infection with herpes simplex virus type 1 (HSV-1) that failed to respond to therapy with both acyclovir and foscarnet. After topical application of HPMPC, the HSV-2 lesions completely resolved. However, the lesions recurred 3 weeks later, and, upon subsequent treatment with HPMPC, regressed. On recurrence, the virus was found to be sensitive to acyclovir, which the patient was given. Again HSV-2, which was resistant to acyclovir, emerged; similar observations were made after another cycle of HPMPC therapy. The HSV-1 isolates were resistant to acyclovir and foscarnet. Following local HPMPC treatment, the lesions regressed, but after 1 week, a second course of topical HPMPC therapy had to be instituted for recurrent infection. The lesions again regressed, and as the recurrent virus was sensitive to acyclovir, the patient was successfully treated with the drug. The results of this study point to the potential usefulness of topical HPMPC in the treatment of immunocompromised patients with HSV-related mucocutaneous infections that are refractory to therapy with acyclovir and/or foscarnet.
Sadzot-Delvaux, Catherine ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Virologie et immunologie - GIGA-M : Coordination scientifique
Tricot, G.
Clumeck, N.
De Clercq, E.
Language :
English
Title :
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Publication date :
1994
Journal title :
Clinical Infectious Diseases
ISSN :
1058-4838
eISSN :
1537-6591
Publisher :
Univ Chicago Press, Chicago, United States - Illinois
Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986;314:686-91:749-57.
Quinnan GV Jr, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984;252:72-7.
Maier JA, Bergman A, Ross MG. Acquired immunodeficiency syndrome manifested by chronic primary genital herpes. Am J Obstet Gynecol 1986;155:756-8.
Whitley RJ, Gnann JW Jr. Acyclovir: a decade iater. N Engl J Med 1992;327:782-9.
Straus SH, Smith HA. Brickman C, de Miranda P, McLaren C, Keeney RE. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982;96: 270-7.
O'Brien JJ, Campoli-Richards DM. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37:233-309.
Collins P, Darby G. Laboratory studies of herpes simplex virus strains resistant to acyclovir. Reviews in Medical Virology 1991;1:19-28.
Nusinoff Lehrman S, Douglas JM. Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy: relation between clinical outcome and in vitro drug sensitivity. Ann Intern Med 1986;104:786-90.
Collins P. Viral sensitivity following the introduction of acyclovir. Am J Med 1988;85(suppl 2a): 129-34.
Wade JC, McLaren C, Meyers JD. Frequency and significance ofacy-clovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983;148:1077-82.
Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982;306:343-6.
Vinckier F, Boogaerts M, De Clerck D, De C'lercq E. Chronic herpetic infection in an immunocompromised patient: report of a case. J Oral Maxillofac Surg 1987;45:723-8.
Sibrack CD, Gutman LT, Wilfert CM, et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 1982;146:673-82.
Erlich KS, Mills J, Chatis P. et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-6.
Schinazi RF, del Bene V, Scott RT, Dudley-Thorpe JB. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses from a patient with an acquired immune deficiency. J Antimicrob Che-mother 1986;18(suppl B): 127—34.
Norris SA, Kessler HA, Fife KH. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS [letter]. J Infect Dis 1988;157:209-10.
Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H. Kohl S. Herpes simplex type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161:711-5.
Birch C.I, Tachedjian G, Doherty RR, Hayes K, Gust ID. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 1990;162:731-4.
Marks GL, Nolan PE, Erlich KS. Ellis MN. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis 1989; 11:474-6.
Coen DM. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res 1991; 15:287-300.
McLaren C, Chen MS, Ghazzouli I, Sarai R, Bums WH. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother 1985;28:740-4.
Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322-8.
Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resislant herpes simplex viruses. Virology 1991;180:793-7.
Ellis MN, Keller PM, Fyfe JA, et al. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 1987:31:1117-25.
Nugier F, Collins P, Larder BA, Langlois M, Aymard M, Darby G. Herpes simplex virus isolates from an immunocompromised patient who failed to respond to acyclovir treatment express thymidine kinase with altered substrate specificity. Antiviral Chemistry and Chemotherapy 1991;2:295-302.
Parker AC, Craig JIO, Collins P, Oliver N, Smith I. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase [letter], Lancet 1987;2:146l.
Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol 1989;70:375-82.
Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex: clinical roles for DNA polymerase mutants and viral heterogeneity. Ann Intern Med 1989; 111:893-9.
Hwang CBC, Ruffner KL, Coen DM. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol 1992;66:1774-6.
Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5.
Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989;320:297-300.
Youle MM, Hawkins DA, Collins P, et al. Acyclovir-resistant herpes in AIDS treated with foscarnet. Lancet 1988;2:341-2.
Erlich KS, Jacobson MA, Koehler JE. et al. Foscarnet therapy of severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS): an uncontrolled trial. Ann Intern Med 1989; 110:710-3.
Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161:1078—84.
Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr 1992;5(suppl l):S29-32.
Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 1992;5(suppl 1):S11-7.
De Clereq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986:323:464-7.
DeClercq E, Sakuma T, Baba M. et al. Antiviral activity of phosphonyl-methoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-72.
Andrei G, Snoeck R, Goubau P. Desmyter J, De Clereq E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur J Clin Microb Infect Dis 1992; 11:143-51.
Maudgal PC, De Clereq E. (S)-l-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. Invest Ophthalmol Vis Sci 1991;32:1816-20.
De Clereq E, Holy A. Efficacy of (.S’)-l-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother 1991;35:701-6.
Yang H. Datema R. Prolonged and potent therapeutic and prophylactic effects of (S)-1 -[(3-hydroxy-2-phosphonylmethoxy)-propyl]cytosine against herpes simplex virus type 2 infections in mice. Antimicrob Agents Chemother 1991;35:1596-600.
Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (£)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1, 3-dihy-droxy-2-propoxymethyl)guanine. and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993;268:6332-7.
Reed LJ, Muench H. A simple method of estimating fifty percent end points. American Journal of Hygiene 1938;27:493-7.
Darville JM. A miniaturised and simplified technique for typing and subtyping herpes simplex virus. J Clin Pathol 1983;36:929-34.
Field HJ, Darby G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother 1980;17:209-16.
Efstathiou S, Kemp S, Darby G, Minson AG. The role of herpes simplex virus type I thymidine kinase in pathogenesis. J Gen Virol 1989;70:869-79.
Field HJ, Coen DM. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol 1986;60:286-9.
Bronson JJ, Ho H-T, De Boeck H, et al. Biochemical pharmacology of acyclic nucleotide analogues. Ann NY AcadSci 1990;616:398-407.
